A systematic approach to surgical hemostat use supports standardization and cost efficiencies

by: Nicole Ferko MSc, Cornerstone Research Group, Burlington, ON, Canada
Walt Danker III PhD and Gaurav Gangoli PharmD, Ethicon Inc., Somerville, NJ, USA

Summary
- A systematic approach to bleeding management, the Hemostasis Optimization Program (HOP), was implemented at a large U.S. teaching hospital.
- Implementation of the HOP framework resulted in an annual cost savings of $168,688.
- This evaluation demonstrated that cost savings, as well as operating room and supply chain efficiencies, were achieved without sacrificing patient outcomes.

Surgical bleeding and variability in hemostat utilization
Disruptive bleeding remains a critical challenge in surgery, as it can lead to suboptimal patient outcomes, introduce procedure complexities for surgeons and surgical staff, and result in higher healthcare costs. For example, uncontrolled bleeding is associated with significantly higher outcomes, introducing procedure complexities for suboptimal patient care, as it can lead to suboptimal patient care, sacrificing patient outcomes, and increasing healthcare costs.

Adjunctive hemostats manage bleeding by acting as mechanical barriers, providing a matrix for clotting, triggering coagulation, and/or sealing adjacent surfaces. Compared to primary methods alone, adjunctive hemostats have been shown to reduce utilization of hospital resources: up to 40% fewer patients require blood transfusions, up to 4 days shorter length of stay, up to 25 minutes reduced operating time, and significantly decreased likelihood of hospital readmission.

A wide array of various types of adjunctive hemostats are available (e.g., absorbable matrices, gels, fibrin sealants, and patches) to accommodate various needs. However, selecting the most appropriate hemostat is challenging given ambiguous bleeding classifications, inconsistent clinical guidance on optimal utilization, and limited indications for use appropriate to specific bleeding situations. These ambiguities can create substantial confusion and potentially unnecessary variability for the management of surgical bleeding, as well as significant clinical and economic hospital burden.

A systematic approach to bleeding management
Because there is no existing universal and practical algorithm that provides guidance for surgical bleeding classification or optimal hemostat utilization, Ethicon, Inc. embarked on a large-scale quantitative research study that characterized hemostat usage. This research involved 450 surgeons from 11 surgical specialties, comprising over 7,800 bleeding occasions. Findings of this endeavor revealed that surgeons decisions for hemostat selection rely predominantly on the surgical bleeding site (anatomy and critical surrounding anatomic structures) and situation (access, tissue surface, bleeding intensity, and bleeding risk). Specifically, the real-world data categorized five universal bleeding situations and the optimal adjunctive hemostat selection for each situation. For example, continuous oozing bleeding would most optimally be addressed with oxidized regenerated cellulose (ORC) (see table). This guidance on the use of adjunctive hemostats in each bleeding situation is based on their physical and biochemical properties, mode of action, and real-world experience use across a broad range of surgical specialties.

Using the data and recommendations from this research, the Hemostasis Optimization Program (HOP) was developed, which focuses on reducing variation in hemostat use and optimizing performance in surgical bleeding management. The program was designed to provide guidance on adjunctive hemostat use through a systematic, step-wise approach that evaluates product use and performance, educates surgical teams, and provides action plans for the healthcare facility:
1. Collect and analyze hospital-specific data on case observations and product utilization
2. Review data and generate action plan regarding hemostat utilization education and evaluation with multidisciplinary team
3. Hold education sessions on topics such as the burden of bleeding, hemostat marketplace clarification, science of hemostasis, and the programs framework and guidance for recommended hemostat use
4. Establish and conduct in-procedure evaluations of the recommended solutions over a set time period
5. Ask surgeons and nursing staff to share experiences and feedback on the programs effectiveness, as well as hurdles encountered and recommended solutions

As part of the program, several key materials are shared to enhance clinical awareness, including educational modules, procedural bleeding guides, and framework algorithms.

<table>
<thead>
<tr>
<th>Bleeding Situation</th>
<th>Definition</th>
<th>Product Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continuous Oozing</td>
<td>Will not stop with compression/simple packing. The solution for this bleeding is more time consuming than it is difficult.</td>
<td>Oxidized Regenerated Cellulose (ORC)</td>
</tr>
<tr>
<td>Problematic</td>
<td>Even though the bleeding is accessible, it could be troublesome. It is more than routine, likely to be resistant to conventional means, requires immediate attention, and causes disruption to the normal progression of surgery.</td>
<td>Fibrin Patch</td>
</tr>
<tr>
<td>Difficult to Access</td>
<td>Bleeding that occurs in tight and irregular spaces; you cannot see the exact source of the bleed. You are concerned that accessing a tight space will cause more harm.</td>
<td>Flowable Gelatin</td>
</tr>
<tr>
<td>Potential Re-Bleeding Risk</td>
<td>Bleeding may be addressed intraoperatively but could later develop into more serious complications, especially in high-risk patients.</td>
<td>Fibrin Sealant</td>
</tr>
<tr>
<td>High-Pressure Vessel Bleeding</td>
<td>A leak in high-pressure vessel (aortic peripheral vascular suture line) that has been stopped, but if it leaks post-op, could be catastrophic.</td>
<td>Vascular Sealant</td>
</tr>
</tbody>
</table>

Real-world evidence at a U.S. hospital
The program has been implemented at hospitals across various countries, and the focus of this paper is the programs impact at a large U.S. teaching hospital. At this hospital, as with most healthcare facilities, optimizing patient outcomes is a top priority. Second to this, cost containment has become essential, with the supply chain team increasingly looking for ways to optimize expenditure without sacrificing patient outcomes.
outcomes. With high volume and variability of hemostat use and product expenditure, implementing the HOP program represented a critical opportunity for the hospital to achieve its goal of continuously improving care based on value and quality.

Such goals are aligned with the “Triple Aim,” “Quadruple Aim,” and the increasing push for value-based healthcare. At the hospital, the Supply Chain team, which has the combined role of product value analysis for perioperative products and inventory management, led the implementation of the HOP program and the conversion of the adjunctive hemostat portfolio to the new manufacturer (Ethicon).

A critical first step for the decision to implement the HOP program was to conduct a clinical and cost value analysis on the integration of the new manufacturer’s hemostats. The results of this analysis showed the potential for substantial cost savings, with similar or superior clinical benefits compared with using hemostats from the previous manufacturer. A trial period, then full conversion, of the adjunctive hemostat category was initiated in 2016. Essentially, the process involved switching 95% of the adjunctive hemostat category from prior manufacturers to a full-line supplier. The suite of value-added solutions offered by the HOP program was a key factor in the conversion decision-making process. Consolidating from two manufacturers to predominately one also facilitated more efficient inventory management. Furthermore, converting to a full-line supplier allowed the hospital to have a broader portfolio of products to address their bleeding management needs.

Lessons were learned from this conversion and program implementation. Obtaining surgeon buy-in was critical to the success of this initiative, and the HOP framework facilitated constructive dialogue. Sharing details on the economic evidence was also critical in validating the process, for example, shifting utilization to more cost-effective products. In addition, education on the rationale for conversion, explanation of product differences and advances over time, and product demonstrations were key factors in obtaining buy-in from clinician and non-clinician stakeholders. Importantly, the support and active engagement of the new manufacturer’s representatives, for continual education on the HOP program during procedures and across the surgical community facilitated comprehensive deployment of this initiative.

Once the hospital achieved value analysis and clinician buy-in, the next step was determining how best to customize and integrate the HOP program, which the Supply Chain team felt was the most comprehensive program of its kind seen at their hospital. A hands-on process was required both inside and outside the operating room to bring in training and manage hurdles. The HOP framework was open to all specialties across all operating rooms; the highest level of interest came from cardiothoracic, vascular, spine, and neurosurgery, where multiple hemostats per procedure are sometimes used. Training was provided through various formats to accommodate different needs for the surgeons and staff, including in-services, audiovisual materials, handouts, presentations, and hands-on product training. To help with seamless delivery and minimize interruption, education was offered across shifts and was integrated into the normal workflow; for example, part of the training occurred at weekly staff meetings. Approximately 100 individuals were trained, including surgeons, nurse managers, inventory personnel, and perioperative technicians.

Finally, a system was set up to track hemostat costs as part of the program implementation. The number of hemostat units, by type, was analyzed to determine hemostat expenditure over a one-year observation period. In addition, a team outside of perioperative supply chain services tracked clinical outcomes, which were continuously monitored for changes in the data over time—no differences were detected before versus after conversion and HOP program implementation.

Achieving the goals
The economic analysis of the program’s impact revealed an annual cost savings of $168,688, not including contractual savings from switching to the full-line supplier. These findings aligned with the predicted savings calculated as part of the project’s initiative. To appropriately compare hemostat costs before and after program implementation, it was necessary to control for several factors, including new products introduced that were not part of the initial analysis, contracted price changes, and the case volume increase that occurred over the one-year observation period. Interestingly, the spend per hemostat unit trended downward 15% over the year (see figure), from a higher average to a lower average spend per unit of product, while case volume trended higher. This hemostat spend optimization was enabled by a shift toward the manufacturer’s more cost-effective products appropriate to each bleeding situation, in particular, advanced ORC hemostats (SURGICEL® SNoW™ Adsorbable Hemostat) and optimal utilization of flowable hemostats (SURGIFLO® Hemostatic Matrix). These findings indicate that the hospital managed the growth of its resource needs well and increasingly optimized its use of adjunctive hemostats over time.

These cost savings and product utilization efficiencies were observed alongside high surgeon and nurse satisfaction. For instance, it was reported that the team of nurses and surgeons were “Very Satisfied” (on a five-point rating scale) with the success of both product conversion and implementation of the HOP program. The hospital also noted improved product education and enhanced communication and support through a solid partnership with the manufacturer, which was integral to the program’s success. Furthermore, operating room efficiencies were observed, which can be partially attributed to having a predominantly single supplier. From a supply chain perspective, inventory monitoring became easier, contracting became more efficient, product waste was reduced, and higher-priced items were eliminated. Periodic evaluation and maintenance strategies were also put in place to ensure continued success.

Final Words
The Hemostasis Optimization Program was effectively implemented, and it represents one of the most comprehensive programs of its kind by this large U.S. teaching hospital. This evaluation demonstrated that cost savings, as well as operating room and supply chain efficiencies, were achieved without sacrificing patient outcomes. In addition, the portfolio conversion and program implementation were met with high staff satisfaction. Manufacturer support and provision of staff resources, through a consultative partnership, were integral to the success of this value-added initiative. The favorable outcomes of this evaluation warrant further partnership with the manufacturer and evaluation of the HOP program, to improve efficiencies in other applicable medical device categories.

References:
EVITHROM® Thrombin, Topical (Human) for Topical Use Only
Lyophilized Powder for Solution

EVITHROM® is a topical thrombin indicated as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical.

EVITHROM® may be used in conjunction with an Absorbable Gelatin Sponge, USP.

Important Safety Information
- For topical use only.
- Do not inject.
- Apply EVITHROM® on the surface of bleeding tissue only.
- The amount of EVITHROM® required depends upon the area of tissue to be treated and the method of application. In clinical studies, volumes up to 10 ml were used in conjunction with Absorbable Gelatin Sponge.
- Do not use for the treatment of severe or brisk arterial bleeding.
- Do not use in individuals known to have anaphylactic or severe systemic reaction to human blood products. Hypersensitivity reactions, including anaphylaxis, may occur.
- There is a potential risk of thrombosis if absorbed systemically.
- May carry a risk of transmitting infectious agents such as viruses and theoretically, the Creutzfeldt-Jakob disease (CJD) agent, despite manufacturing steps designed to reduce the risk of viral transmission.
- The most common adverse reactions during clinical trial (reported in at least 2% of subjects treated with EVITHROM®) were prolonged activated partial thromboplastin time, increased INR, decreased lymphocyte count, prolonged prothrombin time and increased neutrophil count.
- None of the patients treated with EVITHROM developed antibodies to human thrombin or to human Factor V/Va. The clinical significance of these findings is unknown.

For complete indications, contraindications, warnings, precautions, and adverse reactions, please reference full package insert.

SURGIFLO® Hemostatic Matrix Kit Essential Product Information
(Made from Absorbable Gelatin Sponge, USP) with Thrombin

DESCRIPTION
SURGIFLO® with Thrombin (SURGIFLO® Hemostatic Matrix Kit) is intended for hemostatic use by applying to a bleeding surface.

ACTIONS
When used in appropriate amounts SURGIFLO® is absorbed completely within 4 to 6 weeks.

INTENDED USE/INDICATIONS
SURGIFLO®, mixed with thrombin solution, is indicated in surgical procedures (other than ophthalmic) as an adjunct to hemostasis when control of bleeding by ligature or other conventional methods is ineffective or impractical.

CONTRAINDICATIONS
- Do not use SURGIFLO® in intravascular compartments because of the risk of embolization.
- Do not use SURGIFLO® in patients with known allergies to porcine gelatin.
- Do not use SURGIFLO® in closure of skin incisions because it may interfere with the healing of skin edges. This interference is due to mechanical interposition of gelatin and is not secondary to intrinsic interference with wound healing.

WARNINGS
- SURGIFLO® should not be used in the presence of infection and should be used with caution in contaminated areas of the body.
- SURGIFLO® should not be used in instances of pumping arterial hemorrhage. SURGIFLO® will not act as a tampon or plug in a bleeding site.
- SURGIFLO® should be removed from the site of application when used in, around, or in proximity to foramina in bone, areas of bony confine, the spinal cord, and/or the optic nerve and chiasm because it may swell resulting in nerve damage.
- Excess SURGIFLO® should be removed once hemostasis has been achieved.
- The safety and effectiveness of SURGIFLO® for use in ophthalmic procedures has not been established.
- SURGIFLO® should not be used for controlling post-partum intrauterine bleeding or menorrhagia.
- The safety and effectiveness of SURGIFLO® has not been established in children and pregnant women.
- The blue flexible applicator tip should not be trimmed to avoid exposing internal guidewire.
- The white straight applicator tip should be trimmed away from the surgical area. Cut a square angle to avoid creating a sharp tip.

PRECAUTIONS
- Safe and effective use of SURGIFOAM® Sponge has been reported in a published neurologic retrospective study involving 1700 cases in Europe. Safe and effective use in neurosurgery has not been proven through randomized, controlled clinical studies in the United States.
- SURGIFLO® is supplied as a sterile product and cannot be resterilized.
- SURGIFLO® should not be used for packing unless excess product that is not needed to maintain hemostasis is removed. SURGIFLO® may swell up to 20% upon contact with additional fluid.
- SURGIFLO® should not be used in conjunction with autologous blood salvage circuits.
- SURGIFLO® should not be used in conjunction with methylmethacrylate adhesives.
- In urological procedures, SURGIFLO® should not be left in the renal pelvis or ureters to eliminate the potential foci for calculus formation.
ADVERSE EVENTS
A total of 142 patients received SURGIFOAM® Sponge during a clinical trial comparing SURGIFOAM® Sponge to another absorbable gelatin sponge. In general, the following adverse events have been reported with the use of absorbable porcine gelatin-based hemostatic agents:

- Gelatin-based hemostatic agents may serve as a nidus for infection and abscess formation and have been reported to potentiate bacterial growth.
- Giant cell granulomas have been observed at implant sites when used in the brain.
- Compression of the brain and spinal cord resulting from the accumulation of sterile fluid have been observed.
- Multiple neurologic events were reported when absorbable gelatin-based hemostatic agents were used in laminectomy operations, including cauda equina syndrome, spinal stenosis, meningitis, arachnoiditis, headaches, paresthesias, pain, bladder and bowel dysfunction, and impotence.
- The use of absorbable gelatin-based hemostatic agents during the repair of dural defects associated with laminectomy and craniotomy operations, has been associated with fever, infection, leg paresthesias, neck and back pain, bladder and bowel incontinence, cauda equina syndrome, neurogenic bladder, impotence, and paresis.
- The use of absorbable gelatin-based hemostatic agents has been associated with paralysis, due to device migration into foramina in the bone around the spinal cord, and blindness, due to device migration in the orbit of the eye, during lobectomy, laminectomy, and repair of a frontal skull fracture and lacerated lobe.
- Foreign body reactions, “encapsulation” of fluid, and hematoma have been observed at implant sites.
- Excessive fibrosis and prolonged fixation of a tendon have been reported when absorbable gelatin-based sponges were used in severed tendon repair.
- Toxic shock syndrome was reported in association with the use of absorbable gelatin-based hemostats in nasal surgery.
- Fever, failure of absorption, and hearing loss have been observed when absorbable hemostatic agents were used during tympanoplasty.

SURGICEL Essential Product Information

INDICATIONS
SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is used adjunctively in surgical procedures to assist in the control of capillary, venous, and small arterial hemorrhage when ligation or other conventional methods of control are impractical or ineffective. SURGICEL® ORIGINAL, SURGICEL® FIBRILLAR™ and SURGICEL® NU-KNIT® Hemostats can be cut to size for use in endoscopic procedures.

PRECAUTIONS
- Use only as much SURGICEL® Absorbable Hemostat as is necessary for hemostasis, holding it firmly in place until bleeding stops. Remove any excess before surgical closure in order to facilitate absorption and minimize the possibility of foreign body reaction.
- In urological procedures, minimal amounts of SURGICEL® Absorbable Hemostat should be used and care must be exercised to prevent plugging of the urethra, ureter, or a catheter by dislodged portions of the product.
- Since absorption of SURGICEL® Absorbable Hemostat could be prevented in chemically cauterized areas, its use should not be preceded by application of silver nitrate or any other escharotic chemicals.
- If SURGICEL® Absorbable Hemostat is used temporarily to line the cavity of large open wounds, it should be placed so as not to overlap the skin edges. It should also be removed from open wounds by forceps or by irrigation with sterile water or saline solution after bleeding has stopped.
- Precautions should be taken in otorhinolaryngologic surgery to assure that none of the material is aspirated by the patient. (Examples: controlling hemorrhage after tonsillectomy and controlling epistaxis.)
- Care should be taken not to apply SURGICEL® Absorbable Hemostat too tightly when it is used as a wrap during vascular surgery (see Adverse Reactions).

ADVERSE EVENTS
- “Encapsulation” of fluid and foreign body reactions have been reported.
- There have been reports of stenotic effect when SURGICEL® Absorbable Hemostat has been applied as a wrap during vascular surgery.
- Paralysis and nerve damage have been reported when SURGICEL® Absorbable Hemostat was used around, in, or in proximity to foramina in bone, areas of bony confine, the spinal cord, and/or the optic nerve and chiasm.
- Blindness has been reported in connection with surgical repair of a lacerated left frontal lobe when SURGICEL® Absorbable Hemostat was placed in the anterior cranial fossa.
- Possible prolongation of drainage in cholecystectomies and difficulty passing urine per urethra after prostatectomy have been reported.

For more information, please consult your doctor or for product quality and technical questions, call 1-800-795-0012.
SURFLO® Hemostatic Matrix Kit

(Surfactant-Induced-Osmotic Emulsion)

Refrigerate: 2 to 8°C (36°F to 46°F)

SURFLO® Hemostatic Matrix is contraindicated in patients with known allergies to porcine gelatin.

SURFLO® Hemostatic Matrix should not be used for controlling post-partum intrauterine bleeding or for debriding arterial hemorrhage. It should not be used where blood or other fluids have pooled or in cases where the point of hemorrhage is not accessible.

SURFLO® Hemostatic Matrix should not be used in instances of pumping arterial hemorrhage. It should not be used in proximity to foramina in bone, areas of bony confines, the spinal cord, and/or the optic nerve.

SURFLO® Hemostatic Matrix should be removed from the site of application when used in, around, or in proximity to the optic nerve. If signs of vision loss or other neurologic symptoms occur, immediately consult a qualified medical professional.

Use of SURFLO® Hemostatic Matrix as a hemostatic agent for nasal/sinus bleeding:

SURFLO® Hemostatic Matrix may be used in the nose to control bleeding from post-traumatic injuries (such as nasal septal perforation) or surgical procedures. The soaked sponge is replaced as needed. If the patient continues to bleed after the sponge has been replaced, consult a qualified medical professional.

The control patients are included for comparison. Other adverse events observed in less than 5% of the SURFLO® sponge patients include:

Fever, failure of absorption, and hearing loss have been observed when absorbable gelatin-based hemostatic agents have been used during neurosurgery.

For foreign body reactions; “encapsulation” of fluid, and hematoma have been observed at implant sites.

Excessive fibrosis and prolonged fixation of a tendon have been reported when absorbable gelatin-based sponges were used in severe tendon repair.

The safety and effectiveness of SURFLO® Hemostatic Matrix for use in ophthalmic procedures has not been proven through randomized, controlled clinical studies in the United States.

The white straight applicator tip should be trimmed away from the surgical area. Cut a square angle to avoid creating a sharp tip. The tray can be used to contain the excess piece for discarding.

Thrombin should be reconstituted using the vial adapter and the needle-free syringe with Sterile WFI.

Once the hemostatic matrix is mixed with the Thrombin Solution, the appropriate applicator tip should be attached to the syringe for product delivery onto the bleeding site.

Table 1: Summary of effectiveness results comparing SURFIFOAM® Sponge to another absorbable gelatin-based hemostatic agent:

<table>
<thead>
<tr>
<th>Condition</th>
<th>SURFIFOAM® Sponge (n=281)</th>
<th>Control Sponge (n=281)</th>
<th>Total (n=562)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient sera were tested for the presence of anti-porcine collagen immunoglobulins.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sera were collected prior to surgery, at 2 to 4 weeks post-surgery, and at 6 to 8 weeks following surgery.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Table 2: Summary of effectiveness comparing SURFLO® Sponge to another absorbable gelatin sponge (percutaneous achieving hemostasis)

<table>
<thead>
<tr>
<th>Condition</th>
<th>SURFLO® Sponge (n=65)</th>
<th>Control Sponge (n=65)</th>
<th>Total (n=130)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient sera were tested for the presence of anti-porcine collagen immunoglobulins.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sera were collected prior to surgery, at 2 to 4 weeks post-surgery, and at 6 to 8 weeks following surgery.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

A statistical analysis showed that SURFLO® Sponge and the control sponge were equivalent in their ability to achieve hemostasis within 10 minutes. The study also collected data on whether the sponge was still in place at the 2- to 4-week follow-up visit.

Immunoresponses: Patient sera were tested for the presence of anti-porcine collagen immunoglobulins. Nine (7.6%) of the SURFLO® patients and 11 (8.6%) of the control patients had IgG antibodies to porcine collagen at their 6-week follow-up visit. Two hundred six patients were tested at baseline, 2 to 4 weeks, and at 6 to 8 weeks. Only one of the 206 patients had antibodies at baseline, and 6 of the 206 patients had antibodies at the 6- to 8-week follow-up visit. There were no differences in the percentage of patients who had antibodies to porcine collagen at any time point between the different treatments tested in the control group. The analysis of the immunodiagnostics indicated that there was no difference in the triviality of the antibodies to porcine collagen immunoglobulins when compared to the control sponge.

Use of SURFLO® Hemostatic Matrix as a hemostatic agent for nasal/sinus bleeding: SURFLO® Hemostatic Matrix has been successfully used with anterior rhinoscopy techniques as a hemostatic agent for the control of bleeding post-nasal sinus surgery in 10 patients (34 applications sites).

Avoid excessive fluid aspirations. A total of 142 patients received SURFLO® Sponge during a clinical trial comparing SURFLO® Sponge to another absorbable gelatin sponge. The most common adverse events reported during and after the application of the device were headache, tachycardia, and asthenia (a general feeling of weakness). Table 1 lists those adverse events that occurred in greater than 5% of the SURFLO® Sponge patients.
A sterile tray with a vial adapter off the lid from the Flip off the cap from the Once placed in the sterile field, the sterile inner tray may be opened. Open the outer packages and deliver the sterile inner trays to the sterile field using aseptic technique. Opening the tray with Flowable Gelatin Matrix and the tray with Thrombin kit components: For prescribing information on the Thrombin component, please refer to the EVITHROM® Thrombin, Topical (Human), containing 2000 IU. For endoscopic and/or laparoscopic surgical procedures: a. Prepare the selected endoscopic applicator tip according to the product’s labeling. b. Attach the selected endoscopic applicator tip to the SURGIFLO™ Hemostatic Matrix syringe. Make sure that the donor area is clean. c. Express SURGIFLO™ Hemostatic Matrix through the selected applicator tip. Hold the syringe using the product’s labeling. d. Carefully position the selected applicator tip to the tissue where SURGIFLO™ Hemostatic Matrix is to be activated. Be careful to avoid damaging tissue with the cannula. e. While holding the endoscopic applicator in place, express SURGIFLO™ Hemostatic Matrix to the bleeding site. f. If applicable, detach SURGIFLO™ Hemostatic Matrix syringe and introduce the stylet to remove remaining product in the length of the cannula. g. Observe bleeding and repeat application of SURGIFLO™ Hemostatic Matrix if necessary. h. Carefully remove the endoscopic applicator from the tissue post-syringe. SURGIFLO™ Hemostatic Matrix has been delivered to the bleeding site. For endoscopic skin surgery and epistaxis: a. Deliver SURGIFLO™ Hemostatic Matrix to the source of bleeding using the selected applicator tip attached to the syringe that is labeled SURGIFLO™ Hemostatic Matrix. b. Apply sufficient SURGIFLO™ Hemostatic Matrix to cover the entire bleeding surface. Using forceps as an appropriate instrument, carefully layer a sterile saline moistened gauze over the SURGIFLO™ Hemostatic Matrix for 1-2 minutes to ensure the material remains in contact with the bleeding tissue. c. In cases of persistent bleeding, indicated by saturation and bleeding through the material, insert the applicator tip through the center of the mass of previously placed SURGIFLO™ Hemostatic Matrix to deliver fresh material as close as possible to the tissue surface. After repackaging SURGIFLO™ Hemostatic Matrix, use a sterile saline moistened gauze to approximate the material to the bleeding surface, and then remove the tip. Repeat repackaging if necessary. d. Once hemorrhage has been arrested, remove the gauze. If possible, excess SURGIFLO™ Hemostatic Matrix should be removed with gentle irrigation or careful suction. Avoid disrupting the SURGIFLO™ Hemostatic Matrix clot complex. The remaining SURGIFLO™ Hemostatic Matrix does not have to be removed, as it will bioresorb. e. Use of local packing is not necessary when satisfactory hemostasis is achieved. f. In cases of persistent epistaxis or nasal bleeding, the technique can be used in the post-operative period to remove the remaining SURGIFLO™ Hemostatic Matrix. Caution: The use of SURGIFLO™ Hemostatic Matrix for mucosal hemostasis has not been studied. Caution: Federal (U.S.A.) law restricts this device to sale by or on the order of a physician (or properly licensed practitioner).